Hai-bin Shi1, Bo Tang, Yao-Wen Liu, Xue-Feng Wang, Guo-Jun Chen. 1. Department of Neurology, Chongqing Key Laboratory of Neurology, The First Affiliated Hospital of Chongqing Medical University, 1 Youyi Road, Yuzhong District, Chongqing, 400016, China.
Abstract
PURPOSE: Alzheimer disease (AD) and cancer are seemingly two opposite ends of one spectrum. Studies have suggested that patients with AD showed a reduced risk of cancer and vice versa. However, available evidences are not conclusive. So we conducted a meta-analysis using published literatures to systematically examine cancer risk in AD patients. METHODS: A PubMed, EMBASE, and Web of Science search were conducted in May 2014. Pooled risk ratios (RRs) with their corresponding 95 % confidence intervals (CIs) were obtained using random-effects meta-analysis. We tested for publication bias and heterogeneity, and stratified for study characteristics, smoking-related cancers versus nonsmoking-related cancers, and site-specific cancers. RESULTS: Nine studies were included in this meta-analysis. Compared with controls, the pooled RR of cancer in AD patients was 0.55 (95 % CI 0.41-0.75), with significant heterogeneity among these studies (P < 0.001, I(2) = 83.5 %). The reduced cancer risk was more substantial when we restricted analyses to cohort studies, studies with adjusted estimates, studies defining AD by generally accepted criteria, and studies with longer length of follow-up. In sub-analyses for site-specific cancers, only lung cancer showed significant decreased risk (RR 0.72; 95 % CI 0.56-0.91). We did not find significant publication bias (P = 0.251 for Begg and Mazumdar's test and P = 0.143 for Egger's regression asymmetry test). CONCLUSION: These results support an association between AD and decreased cancer risk.
PURPOSE:Alzheimer disease (AD) and cancer are seemingly two opposite ends of one spectrum. Studies have suggested that patients with AD showed a reduced risk of cancer and vice versa. However, available evidences are not conclusive. So we conducted a meta-analysis using published literatures to systematically examine cancer risk in ADpatients. METHODS: A PubMed, EMBASE, and Web of Science search were conducted in May 2014. Pooled risk ratios (RRs) with their corresponding 95 % confidence intervals (CIs) were obtained using random-effects meta-analysis. We tested for publication bias and heterogeneity, and stratified for study characteristics, smoking-related cancers versus nonsmoking-related cancers, and site-specific cancers. RESULTS: Nine studies were included in this meta-analysis. Compared with controls, the pooled RR of cancer in ADpatients was 0.55 (95 % CI 0.41-0.75), with significant heterogeneity among these studies (P < 0.001, I(2) = 83.5 %). The reduced cancer risk was more substantial when we restricted analyses to cohort studies, studies with adjusted estimates, studies defining AD by generally accepted criteria, and studies with longer length of follow-up. In sub-analyses for site-specific cancers, only lung cancer showed significant decreased risk (RR 0.72; 95 % CI 0.56-0.91). We did not find significant publication bias (P = 0.251 for Begg and Mazumdar's test and P = 0.143 for Egger's regression asymmetry test). CONCLUSION: These results support an association between AD and decreased cancer risk.
Authors: Arthur A Nery; Rodrigo R Resende; Antonio H Martins; Cleber A Trujillo; Vesna A Eterovic; Henning Ulrich Journal: J Mol Neurosci Date: 2010-05-12 Impact factor: 3.444
Authors: Jane A Driver; Alexa Beiser; Rhoda Au; Bernard E Kreger; Greta Lee Splansky; Tobias Kurth; Douglas P Kiel; Kun Ping Lu; Sudha Seshadri; Phillip A Wolf Journal: BMJ Date: 2012-03-12
Authors: Michele Salemi; Maria Paola Mogavero; Giuseppe Lanza; Laura M Mongioì; Aldo E Calogero; Raffaele Ferri Journal: Cells Date: 2022-06-15 Impact factor: 7.666
Authors: Kimberly D van der Willik; Rikje Ruiter; Frank J Wolters; M Kamran Ikram; Bruno H Stricker; Michael Hauptmann; Annette Compter; Sanne B Schagen; M Arfan Ikram Journal: Neuroepidemiology Date: 2018-05-14 Impact factor: 3.282
Authors: Stephanie I Alfonso; Julia A Callender; Basavaraj Hooli; Corina E Antal; Kristina Mullin; Mathew A Sherman; Sylvain E Lesné; Michael Leitges; Alexandra C Newton; Rudolph E Tanzi; Roberto Malinow Journal: Sci Signal Date: 2016-05-10 Impact factor: 8.192
Authors: Summer B Gibson; Diana Abbott; James M Farnham; Khanh K Thai; Hailey McLean; Karla P Figueroa; Mark B Bromberg; Stefan M Pulst; Lisa Cannon-Albright Journal: Neurology Date: 2016-05-11 Impact factor: 9.910